drugset / Trial / NCT00101725

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

NCT00101725

Phase 2 Completed 245 enrolled Bausch Health Americas, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is designed to evaluate the safety and effectiveness of an investigational drug, TRN-002 (crofelemer) to relieve the symptoms of diarrhea-predominant irritable bowel syndrome (IBS).

Timeline

Start
2004-12
Primary completion
2005-11
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Crofelemer Small molecule 125 mg Oral
Subject Crofelemer Small molecule 250 mg Oral
Subject Crofelemer Small molecule 500 mg Oral